Table 1

 Total cholesterol, high-density lipoprotein- cholesterol, triglycerides (mmol/l), apolipoprotein A1 (apo A1), apolipoprotein B (apo B; g/l) and the atherogenic index and apo B/apo A-1 ratio during treatment with infliximab

VariableBaseline6 weeks22 weeks48 weeks
apo B:apo A1, apolipoprotein B:apolipoprotein A1 ratio; HDL, high-density lipoprotein.
*p<0.05 Compared with baseline (performed by general estimation equation analyses).
Median (range) total cholesterol (mmol/l)4.79 (2.70–8.10)5.08 (2.79–9.18)*4.94 (2.90–10.42)*4.81 (3.21–7.29)
Mean (SD) HDL-cholesterol (mmol/l)1.46 (0.50)1.61 (0.54)*1.55 (0.53)*1.53 (0.51)
Median (range) atherogenic index3.42 (1.74–7.78)3.20 (1.59–8.63)*3.43 (1.67–8.08)3.38 (1.62–10.70)
Median (range) triglycerides (mmol/l)1.26 (0.62–4.40)1.39 (0.52–3.80)*1.32 (0.46–3.36)1.26 (0.62–3.48)
Mean (SD) apo A1 (g/l)1.58 (0.35)1.70 (0.33)*1.65 (0.33)*1.65 (0.33)*
Mean (SD) apo B (g/l)0.93 (0.23)0.95 (0.24)0.94 (0.24)0.93 (0.19)
Mean (SD) apo B:Apo A1 ratio0.62 (0.20)0.58 (0.20)*0.59 (0.18)0.59 (0.16)